Targeting protein arginine N-methyltransferases with peptide-based inhibitors: Opportunities and challenges

Future Medicinal Chemistry

Volumn 5, Issue 18, 2013, Pages 2199-2206

  Vhuiyan, Mynol ^a   Thomas, Dylan ^a   Hossen, Farhad ^a   Frankel, Adam ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HISTONE H4; N(G),N(G) DIMETHYLARGININE; PEPTIDE; PROTEIN ARGININE METHYLTRANSFERASE; SINEFUNGIN;

AMINO ACID SEQUENCE; CELL STRAIN MCF 7; CHEMICAL MODIFICATION; DIMERIZATION; ENZYME ACTIVITY; EPIGENETICS; METHYLATION; MOLECULAR PROBE; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

PEPTIDES; PROTEIN-ARGININE N-METHYLTRANSFERASES; SUBSTRATE SPECIFICITY;

EID: 84889575945     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.184     Document Type: Review

References (36)

1. Albericio F, Kruger HG. Therapeutic peptides. Future Med. Chem. 4(12), 1527-1531 (2012).
2. Ahrens VM, Bellmann-Sickert K, Beck- Sickinger AG. Peptides and peptide conjugates: therapeutics on the upward path. Future Med. Chem. 4(12), 1567-1586 (2012).
3. Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. Nat. Rev. Cancer. 13(1), 37-50 (2013).
4. Bedford MT, Clarke SG. Protein arginine methylation in mammals: who, what, and why. Mol. Cell 33(1), 1-13 (2009).
5. Di Lorenzo A, Bedford MT. Histone arginine methylation. FEBS Lett. 585(13), 2024-2031 (2011).
6. Yost JM, Korboukh I, Liu F, Gao C, Jin J. Targets in epigenetics: inhibiting the methyl writers of the histone code. Curr. Chem. Genomics 5(Suppl. 1), 72-84 (2011).
7. Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat. Rev. Drug Discov. 8(9), 724-732 (2009).
8. Cha B, Jho EH. Protein arginine methyltransferases (PRMTs) as therapeutic targets. Expert Opin. Ther. Targets 16(7), 651-664 (2012).
9. Lakowski TM, t Hart P, Ahern CA, Martin NI, Frankel A. Neta-substituted arginyl peptide inhibitors of protein arginine N-methyltransferases. ACS Chem. Biol. 5(11), 1053-1063 (2010).
10. Gary JD, Clarke S. RNA and protein interactions modulated by protein arginine methylation. Prog. Nucleic Acid Res. Mol. Biol. 61, 65-131 (1998).
11. Wooderchak WL, Zang T, Zhou ZS, Acuna M, Tahara SM, Hevel JM. Substrate profiling of PRMT1 reveals amino acid sequences that extend beyond the RGG' paradigm. Biochemistry 47(36), 9456-9466 (2008).
12. Zhang X, Cheng X. Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides. Structure 11(5), 509-520 (2003). (Pubitemid 36579129)
13. Kolbel K, Ihling C, Kuhn U et al. Peptide backbone conformation affects the substrate preference of protein arginine methyltransferase I. Biochemistry 51(27), 5463-5475 (2012).
14. Osborne TC, Obianyo O, Zhang X, Cheng X, Thompson PR. Protein arginine methyltransferase 1: positively charged residues in substrate peptides distal to the site of methylation are important for substrate binding and catalysis. Biochemistry 46(46), 13370-13381 (2007). (Pubitemid 350136376)
15. Gui S, Wooderchak-Donahue WL, Zang T et al. Substrate-induced control of product formation by protein arginine methyltransferase 1. Biochemistry 52(1), 199-209 (2013).
16. Cheng D, Cote J, Shaaban S, Bedford MT. The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing. Mol. Cell 25(1), 71-83 (2007). (Pubitemid 46049059)
17. Lakowski TM, Frankel A. Kinetic analysis of human protein arginine N-methyltransferase 2: formation of monomethyl- and asymmetric dimethyl-arginine residues on histone H4. Biochem. J. 421(2), 253-261 (2009).
18. Boisvert FM, Chenard CA, Richard S. Protein interfaces in signaling regulated by arginine methylation. Sci. STKE 2005(271), re2 (2005).
19. Sack JS, Thieffine S, Bandiera T et al. Structural basis for CARM1 inhibition by indole and pyrazole inhibitors. Biochem. J. 436(2), 331-339 (2011).
20. Martin NI, Liskamp RM. Preparation of N(G)-substituted l-arginine analogues suitable for solid phase peptide synthesis. J. Org. Chem. 73(19), 7849-7851 (2008).
21. Thomas D, Lakowski TM, Pak ML, Kim JJ, Frankel A. Forster resonance energy transfer measurements of cofactor-dependent effects on protein arginine N-methyltransferase homodimerization. Protein Sci. 19(11), 2141-2151 (2010).
22. t Hart P, Thomas D, van Ommeren R, Lakowski TM, Frankel A, Martin NI. Analogues of the HIV-Tat peptide containing N?-modified arginines as potent inhibitors of protein arginine N-methyltransferases. Med. Chem. Commun. 3, 1235-1244 (2012).
23. Pugh CS, Borchardt RT, Stone HO. Sinefungin, a potent inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2'-)-methyltransferase, and viral multiplication. J. Biol. Chem. 253(12), 4075-4077 (1978). (Pubitemid 8380622)
24. Couture JF, Hauk G, Thompson MJ, Blackburn GM, Trievel RC. Catalytic roles for carbon-oxygen hydrogen bonding in SET domain lysine methyltransferases. J. Biol. Chem. 281(28), 19280-19287 (2006). (Pubitemid 44035432)
25. Dowden J, Hong W, Parry RV, Pike RA, Ward SG. Toward the development of potent and selective bisubstrate inhibitors of protein arginine methyltransferases. Bioorg. Med. Chem. Lett. 20(7), 2103-2105 (2010).
26. Dowden J, Pike RA, Parry RV, Hong W, Muhsen UA, Ward SG. Small molecule inhibitors that discriminate between protein arginine N-methyltransferases PRMT1 and CARM1. Org. Biomol. Chem. 9(22), 7814-7821 (2011).
27. t Hart P, Lakowski TM, Thomas D, Frankel A, Martin NI. Peptidic partial bisubstrates as inhibitors of the protein arginine N-methyltransferases. ChemBioChem 12(9), 1427-1432 (2011).
28. Osborne T, Roska RL, Rajski SR, Thompson PR. In situ generation of a bisubstrate analogue for protein arginine methyltransferase 1. J. Am. Chem. Soc. 130(14), 4574-4575 (2008). (Pubitemid 351500080)
29. Luo Y, Knuckley B, Lee YH, Stallcup MR, Thompson PR. A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation. J. Am. Chem. Soc. 128(4), 1092-1093 (2006). (Pubitemid 43190618)
30. Obianyo O, Causey CP, Osborne TC et al. A chloroacetamidine-based inactivator of protein arginine methyltransferase 1: design, synthesis, and in vitro and in vivo evaluation. ChemBioChem 11(9), 1219-1223 (2010).
31. Obianyo O, Causey CP, Jones JE, Thompson PR. Activity-based protein profiling of protein arginine methyltransferase 1. ACS Chem. Biol. 6(10), 1127-1135 (2011).
32. Bicker KL, Obianyo O, Rust HL, Thompson PR. A combinatorial approach to characterize the substrate specificity of protein arginine methyltransferase 1. Mol. Biosyst 7(1), 48-51 (2011).
33. Ragno R, Simeoni S, Castellano S et al. Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations. J. Med. Chem. 50(6), 1241-1253 (2007). (Pubitemid 46496324)
34. Spannhoff A, Heinke R, Bauer I et al. Target-based approach to inhibitors of histone arginine methyltransferases. J. Med. Chem. 50(10), 2319-2325 (2007). (Pubitemid 46799244)
35. Heinke R, Spannhoff A, Meier R et al. Virtual screening and biological characterization of novel histone arginine methyltransferase PRMT1 inhibitors. ChemMedChem 4(1), 69-77 (2009).
36. Wang J, Chen L, Sinha SH et al. Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation. J. Med. Chem. 55(18), 7978-7987 (2012).